

From: [REDACTED]@cantourage.com>
Sent: Tue, 19 Nov 2024 16:30:29 +0000
To: [REDACTED]@mhra.gov.uk>;
[REDACTED]
Cc: [REDACTED]@cantourage.co.uk"; [REDACTED]@cantourage.co.uk>
Subject: Re: CANTOURAGE UK LIMITED - MHRA GDP Inspection - Post-Inspection Letter

Good afternoon [REDACTED]

I am writing to confirm whether you have received our post-inspection letter submitted on 12th November 2024. We want to ensure that the letter has reached you without issue and would appreciate if you could kindly acknowledge receipt at your earliest convenience.

If you require any further information or documentation from our side, please do not hesitate to let me know.

Thank you for your time and assistance.

Warm regards,

[REDACTED]

From: [REDACTED]
Date: Tuesday, 12 November 2024 at 17:58
To: [REDACTED]
Cc: [REDACTED]@cantourage.co.uk
Subject: Re: CANTOURAGE UK LIMITED - MHRA GDP Inspection - Post-Inspection Letter

Good evening [REDACTED]

Please find attached our response to the deficiencies noted in your post-inspection letter, along with the anticipated completion dates for each item.

We would be grateful if the MHRA could prioritise the approval of our variation and new WDA. Despite our continued [REDACTED], we have not yet received confirmation regarding the issuance of a [REDACTED] for our new site. As discussed during the inspection, we understand this is due to [REDACTED] policy of only arranging site visits after issuance of the updated WDA.

[REDACTED] As such, receiving the updated WDA at your earliest convenience could significantly alleviate this avoidable burden.

Please do not hesitate to reach out if further clarification or information is required. We appreciate your assistance and look forward to your response.

Warm regards,

From: [REDACTED]
Date: Thursday, 17 October 2024 at 15:24
To: [REDACTED]
Cc: [REDACTED]
Subject: CANTOURAGE UK LIMITED - MHRA GDP Inspection - Post-Inspection Letter

Good Afternoon,

Please find attached a copy of your post-inspection letter.

Kind regards,

[REDACTED]
Senior GDP Inspector
Standards and Compliance
Healthcare, Quality and Access



Medicines & Healthcare products
Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU

Email: [REDACTED]

Mobile: [REDACTED]

Stay connected: [mhra.gov.uk/stayconnected](https://www.mhra.gov.uk/stayconnected)

[Read our guidance on coronavirus \(COVID-19\)](#)

MHRA officers endeavour to ensure that advice and comments offered reflect MHRA operational inspectorate policy and a science and risk based approach to the matters raised. You should note that any technical or regulatory advice given to you is not legally binding with regard to any future application(s) for the concerned site or products. Furthermore, advice cannot be taken as indicative of any future agreed position during inspection.

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click

[DHTermsAndConditions](#)